Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in STAAR Surgical Company or Teleflex Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how STAAR Surgical Company and Teleflex Incorporated compare based on key financial metrics to determine which better meets your investment needs.

About STAAR Surgical Company and Teleflex Incorporated

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Latest Health Care Equipment & Supplies and STAAR Surgical Company, Teleflex Incorporated Stock News

As of September 11, 2026, STAAR Surgical Company had a $1.1 billion market capitalization, compared to the Health Care Equipment & Supplies median of $385.8 million. STAAR Surgical Company’s stock is down 2.1% in 2026, down 3.7% in the previous five trading days and down 18.08% in the past year.

Currently, STAAR Surgical Company’s price-earnings ratio is 294.3. STAAR Surgical Company’s trailing 12-month revenue is $339.6 million with a 1.1% net profit margin. Year-over-year quarterly sales growth most recently was 111.1%. Analysts expect adjusted earnings to reach $0.763 per share for the current fiscal year. STAAR Surgical Company does not currently pay a dividend.

As of September 11, 2026, Teleflex Incorporated had a $5.6 billion market cap, putting it in the 69th percentile of all stocks. Teleflex Incorporated’s stock is up 7.2% in 2026, down 5.4% in the previous five trading days and up 0.54% in the past year.

Currently, Teleflex Incorporated does not have a price-earnings ratio. Teleflex Incorporated’s trailing 12-month revenue is $2.3 billion with a -45.8% net profit margin. Year-over-year quarterly sales growth most recently was 28.9%. Analysts expect adjusted earnings to reach $7.076 per share for the current fiscal year. Teleflex Incorporated currently has a 1.0% dividend yield.

How We Compare STAAR Surgical Company and Teleflex Incorporated Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at STAAR Surgical Company and Teleflex Incorporated’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

STAAR Surgical Company and Teleflex Incorporated Stock Value Grades

Company	Ticker	Value
STAAR Surgical Company	STAA	F
Teleflex Incorporated	TFX	C

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

STAAR Surgical Company has a Value Score of 15, which is Ultra Expensive. Teleflex Incorporated has a Value Score of 41, which is Average.

The Value Stock Winner: No Clear Winner

Neither STAAR Surgical Company or Teleflex Incorporated has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if STAAR Surgical Company or Teleflex Incorporated is the better investment when it comes to value.

STAAR Surgical Company and Teleflex Incorporated’s Momentum Grades

Company	Ticker	Momentum
STAAR Surgical Company	STAA	D
Teleflex Incorporated	TFX	C

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

STAAR Surgical Company has a Momentum Score of 26, which is Weak. Teleflex Incorporated has a Momentum Score of 43, which is Average.

The Momentum Stock Winner: No Clear Winner

Neither STAAR Surgical Company or Teleflex Incorporated has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if STAAR Surgical Company or Teleflex Incorporated is the better investment when it comes to momentum.

STAAR Surgical Company and Teleflex Incorporated’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
STAAR Surgical Company	STAA	B
Teleflex Incorporated	TFX	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

STAAR Surgical Company has a Earnings Estimate Score of 63, which is Positive. Teleflex Incorporated has a Earnings Estimate Score of 64, which is Positive.

The Earnings Estimate Revisions Grade Winner: It’s a Tie!

Looking at the Earnings Estimate Revisions Grade breakdown above, both STAAR Surgical Company and Teleflex Incorporated have a grade of B. For those focusing solely on a company’s estimate revisions, other financial metrics will need to be evaluated to determine whether STAAR Surgical Company or Teleflex Incorporated is a better fit.

Other STAAR Surgical Company and Teleflex Incorporated Grades

In addition to Estimate Revisions, Value and Momentum, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether STAAR Surgical Company and Teleflex Incorporated pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, STAAR Surgical Company or Teleflex Incorporated Stock?

Overall, STAAR Surgical Company stock has a Value Score of 15, Momentum Score of 26 and Estimate Revisions Score of 63.

Teleflex Incorporated stock has a Value Score of 41, Momentum Score of 43 and Estimate Revisions Score of 64.

Comparing STAAR Surgical Company and Teleflex Incorporated’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.